An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback